Production (Stage)
Universal Ibogaine Inc.
IBOGF
$0.018
-$0.0003-1.64%
OTC PK
| 04/30/2025 | 01/31/2025 | 10/31/2024 | 07/31/2024 | 04/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 493.20K | 261.50K | 314.30K | 408.00K | 395.50K |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 493.20K | 261.50K | 314.30K | 408.00K | 395.50K |
| Cost of Revenue | 313.90K | 253.40K | 324.60K | 331.60K | 331.00K |
| Gross Profit | 179.30K | 8.10K | -10.40K | 76.30K | 64.50K |
| SG&A Expenses | 130.40K | 124.70K | 132.60K | 24.00K | 325.10K |
| Depreciation & Amortization | 56.60K | 62.70K | 58.90K | 71.10K | 59.30K |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 512.60K | 440.80K | 538.20K | 493.80K | 715.30K |
| Operating Income | -19.40K | -179.30K | -223.90K | -85.80K | -319.80K |
| Income Before Tax | -46.60K | -214.20K | -253.90K | -554.40K | -635.50K |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -46.60K | -214.20K | -253.90K | -554.40K | -635.50K |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -46.60K | -214.20K | -253.90K | -554.40K | -635.50K |
| EBIT | -19.40K | -179.30K | -223.90K | -85.80K | -319.80K |
| EBITDA | 37.20K | -116.60K | -165.00K | -14.70K | -260.60K |
| EPS Basic | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Normalized Basic EPS | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS Diluted | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Normalized Diluted EPS | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Average Basic Shares Outstanding | 308.61M | 308.61M | 308.61M | 263.35M | 284.45M |
| Average Diluted Shares Outstanding | 308.61M | 308.61M | 308.61M | 263.35M | 284.45M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |